FTC challenges ‘junk’ patents held by 10 drugmakers, including for Novo Nordisk’s Ozempic CNBCFTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs The Wall Street JournalUS challenges ‘bogus’ patents on Ozempic and other drugs in effort to spur competition ABC NewsFTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic Pricier—Here’s How ForbesRecon: FTC warns drugmakers over ‘junk’ Orange Book patents; FDA solicits public feedback on advisory committee reforms Regulatory Focus